期刊文献+

初诊多发性骨髓瘤患者外周血ALC与临床特征及预后的关系 被引量:3

Association of peripheral ALC with clinical features and prognosis in newly diagnosed multiple myeloma patients
下载PDF
导出
摘要 目的探讨多发性骨髓瘤(multiple myeloma,MM)患者初诊外周血淋巴细胞绝对数(absolute lymphocyte count,ALC)与临床特征及预后的关系。方法回顾性分析初诊MM患者50例。根据中位ALC水平(1.46×109/L),将其分为ALC低水平组(ALC<1.46×109/L)和ALC高水平组(ALC≥1.46×109/L)各25例。根据临床资料及实验室检查结果分析ALC与初诊MM患者的临床特征和预后的关系。结果 ALC低水平组外周血白细胞(white blood cell,WBC)计数、血红蛋白(hemoglobin,Hb)和血小板(platelet,Plt)计数指标均低于ALC高水平组(均P<0.05)。ALC低水平组血清乳酸脱氢酶(lactate dehydrogenase,LDH)值和β2-微球蛋白(β2-microglobulin,β2-MG)指标均高于ALC高水平组(均P<0.05)。ALC低水平组和ALC高水平组治疗后缓解例数分别为13例(52.0%)和18例(72.0%),两组比较差异无统计学意义(P=0.075)。ALC低水平组患者生存率低于ALC高水平组(56.0%vs 80.0%,P<0.05)。结论初诊ALC水平低的患者生存率较低。ALC水平与MM的多个预后因素密切相关,可考虑作为MM判断预后的辅助指标。 Objective To investigate the association of peripheral blood lymphocyte count( ALC) with clinical features and prognosis in newly diagnosed multiple myeloma( MM) patients. Methods Fifty MM patients were enrolled in the study,including 25 cases with low ALC level(〈 1. 46 × 109/L) and 25 cases with high ALC level( ≥1. 46 × 109/L).The association of ALC with clinical characteristics and prognosis of MM patients were analyzed. Results The peripheral blood white blood cell count( WBC),hemoglobin( Hb) and platelet count( Plt) were all lower in patients with low ALC level than those in patients with high ALC( all P〈0. 05). The levels of lactate dehydrogenase( LDH) and β2-microglobulin( β2-MG) were higher in patients with low ALC than those in patients with high ALC( both P〈0. 05). Thirteen cases( 52. 0%) and 18 cases( 72. 0%) achieved clinical remission in patients with low and high ALC levels,respectively( P =0. 075). The survival rate of low ALC patients was lower than that of high ALC patients( 56. 0% vs 80. 0%,P〈0. 05).Conclusion Newly diagnosed MM patients who have low ALC level tend to have a lower survival rate. The ALC level is closely related to multiple prognostic factors of MM and can be used as a marker for MM prognosis.
作者 郑方英 张晓玲 王春莲 Zheng Fangying Zhang Xiaoling Wang Chunlian(Department of Hemopathology, Huizhou First People' s Hospital, Huizhou 516003, China)
出处 《实用肿瘤杂志》 CAS 2017年第4期352-355,共4页 Journal of Practical Oncology
关键词 多发性骨髓瘤 淋巴细胞计数 T淋巴细胞亚群/免疫学 预后 回顾性研究 multiple myeloma lymphocyte count T-lymphocyte subsets/immunology prognosis retrospective studies
  • 相关文献

参考文献11

二级参考文献102

  • 1Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma[J]. Br J Haematol, 2007,138(5) :563-579.
  • 2Hori S,Nomura T,Sakaguchi S. Control of regulatory T cell development by the transcription factor FoxP3 [J]. Science, 2003,299 (5609) :1057-1061.
  • 3Oken MM, Kay NE. T cell subpopulations in multiple myeloma: correlation with clinical disease status[J]. Br J Haematol, 1981,49 (4) : 629-634.
  • 4Jonuleit H, Schmitt E, Kakirman H, et al. Infectious tolerance: human CD25 (+) regulatory T cells convey suppressor activity to conventional CD4 (+) T helper cells [J]. J Exp Med,2002,196(2) :255-260.
  • 5Victor H, Jimenez-Zepeda VH, Braggio E, et al.Dissecting karyotypic patterns in non-hyperdiploid multiple myeloma: an overview on the karyotypic evolution[ J ]. Clin Lymphoma Myeloma Leuk, 2013, 13 (5) :552 -558.
  • 6Faiman B. Myeloma genetics and genomics: practice implications and future directions [ J ]. Clin Lymphoma Myeloma Leuk ,2014,14 ( 6 ) :436 - 440.
  • 7Lim JH, Seo EJ, Park CJ,et al. Cytogenetic classification in Korean multiple myeloma patients : prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities [ J ]. Eur J Haematol,2014,92(4) :313 - 320.
  • 8Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines [ J ]. Mayo Clin Proc, 2013,88(4) :360 - 376.
  • 9Stewart AK, Trudel S, Bahlis N J, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after AHSCT in patients with MM with a quality-of-life assessment [ J ]. Blood, 2013, 121 (9) :1517 - 1523.
  • 10Kumar S, Flinn I, Richardson PG, et al. Randomized, multieenter,phase 2 study ( EVOLUTION ) of combina- tions of bortezomib, dexamethasone, eyclophosphamide, and lenalidomide in previously untreated multiple myeloma[ J]. Blood, 2012,119 (19) :4375 - 4382.

共引文献113

同被引文献15

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部